Adverse Events Associated with Devices for Incisional Glaucoma Surgery Performed with Implants as Reported to the FDA MAUDE Database.
Chen Kaylie, Pendri Pooja, Kovacs Kyle, Van Tassel Sarah H
AI Summary
This study analyzed FDA MAUDE data on incisional glaucoma implants, finding hypotony, device-iris touch, and occlusion as common adverse events, crucial for surgeon counseling and surgical planning.
Abstract
Purpose
Incisional glaucoma surgery is indicated in advanced glaucoma or glaucoma refractory to less invasive therapies, and can be performed with implants to lower IOP including glaucoma drainage or filtration devices. The Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) represents the largest U.S. publicly-available repository of device-related incisional glaucoma surgery complications, enabling insight into complications experienced with incisional glaucoma surgery in real-world practice to develop a risk profile for the use of each device.
Methods
MAUDE database was searched between January-2012 and December-2021 for Brand Name: Ahmed ClearPath, Ahmed Glaucoma Valve, Baerveldt, Ex-PRESS, and Molteno. Reports were categorized by complication;when multiple were present, multiple categories were attributed. Reports with identical text and dates were counted as duplicate and excluded. Literature reports comparing multiple devices without clear device specification per complication were excluded.
Results
The search yielded 1538 reports, of which 1379 reports describing 2429 adverse events met inclusion criteria. The most common events for were hypotony/hypotony maculopathy (284), device-iris touch (282), device occlusion (213), elevated IOP (210), and device explanted due to possible exclusion (176). Delivery system failures occurred (166). Patients also experienced flat/shallow anterior chambers (147) and corneal edema/bullous keratopathy/endothelial cell count reduction/corneal decompensation/Descemet's membrane tears (128).
Conclusion
By drawing on the real-world complications collected in the MAUDE database, this study identifies adverse events of greatest clinical pertinence for device-related incisional glaucoma surgery overall and by brand. Understanding the most common adverse events may support surgeons in counseling patients and preparing for device implantation.
MeSH Terms
Shields Classification
Key Concepts6
The most common adverse events reported for incisional glaucoma surgery devices (Ahmed ClearPath, Ahmed Glaucoma Valve, Baerveldt, Ex-PRESS, and Molteno) in the MAUDE database (1379 reports, 2429 adverse events) were hypotony/hypotony maculopathy (284 events), device-iris touch (282 events), device occlusion (213 events), elevated IOP (210 events), and device explantation due to possible exclusion (176 events).
Delivery system failures occurred in 166 events for incisional glaucoma surgery devices (Ahmed ClearPath, Ahmed Glaucoma Valve, Baerveldt, Ex-PRESS, and Molteno) as reported in the MAUDE database (1379 reports, 2429 adverse events).
Patients undergoing incisional glaucoma surgery with implants (Ahmed ClearPath, Ahmed Glaucoma Valve, Baerveldt, Ex-PRESS, and Molteno) experienced flat/shallow anterior chambers (147 events) and corneal edema/bullous keratopathy/endothelial cell count reduction/corneal decompensation/Descemet's membrane tears (128 events) as reported in the MAUDE database (1379 reports, 2429 adverse events).
Incisional glaucoma surgery with implants (Ahmed ClearPath, Ahmed Glaucoma Valve, Baerveldt, Ex-PRESS, and Molteno) is indicated in advanced glaucoma or glaucoma refractory to less invasive therapies.
The FDA Manufacturer and User Facility Device Experience (MAUDE) database represents the largest U.S. publicly-available repository of device-related incisional glaucoma surgery complications.
A search of the MAUDE database between January 2012 and December 2021 for incisional glaucoma surgery devices (Ahmed ClearPath, Ahmed Glaucoma Valve, Baerveldt, Ex-PRESS, and Molteno) yielded 1538 reports, of which 1379 reports describing 2429 adverse events met inclusion criteria.
Related Articles5
Anterior Chamber Washout During Ahmed Valve Glaucoma Surgery Reduces the Incidence of Hypertensive Phase.
Case SeriesPREVALENCE, CHARACTERISTICS, AND OUTCOMES OF RHEGMATOGENOUS RETINAL DETACHMENT IN EYES WITH TRABECULECTOMY OR GLAUCOMA DRAINAGE DEVICES.
Cohort StudyThree-Year Outcomes of Pars Plana Ahmed and Baerveldt Glaucoma Implantations for Neovascular Glaucoma in Japanese Eyes.
Cohort StudyClinical Outcomes After Ahmed Glaucoma Valve Implantation for Pediatric Glaucoma After Congenital Cataract Surgery.
Cohort StudyIncidence and Outcomes of Suprachoroidal Hemorrhage Following Aurolab Aqueous Drainage Implant in Adult and Pediatric Glaucoma.
Case SeriesIs this article assigned to the wrong chapter(s)? Let us know.